Here is the complete, fully sourced reference:
OCD vs OCPD - Complete Clinical Reference
PART 1: OCD vs OCPD - Key Differences
These two disorders share a name fragment but are fundamentally different in nature, phenomenology, and treatment approach.
| Feature | OCD | OCPD |
|---|
| DSM Category | Axis I / Clinical Syndrome - Obsessive-Compulsive and Related Disorder | Axis II / Cluster C Personality Disorder |
| Core feature | Recurrent intrusive obsessions + compulsive rituals | Pervasive pattern of perfectionism, orderliness, and mental/interpersonal control |
| Ego quality | Ego-dystonic - symptoms are alien, unwanted, and distressing to the patient | Ego-syntonic - traits are acceptable to the patient, viewed as rational or correct |
| Insight | Patient usually recognizes symptoms as excessive or unreasonable | Patient sees their behavior as the "right" way; no awareness of a problem |
| Anxiety | High - obsessions generate marked anxiety; compulsions temporarily reduce it | Low - perfectionism does not produce anxiety in the patient themselves |
| Symptom content | Specific obsessions (contamination, harm, symmetry, blasphemous/sexual thoughts) + specific neutralizing rituals | Perfectionism, preoccupation with rules/lists/schedules, miserliness, workaholism, rigidity, hoarding of worn-out objects |
| True compulsions | Yes - repetitive behaviors or mental acts driven by obsessions or rigid rules | No - behavior is controlled and deliberate, not driven by obsession-neutralization |
| Onset | Childhood/adolescence common; mean ~20 years | Traits present from early adulthood, pervasive across all contexts |
| Course | Episodic or chronic, waxing and waning | Stable, lifelong personality pattern |
| Help-seeking | Patients frequently seek help - they are distressed | Patients rarely seek help; deny problems; impervious to feedback |
| Interpersonal style | Variable; shame causes concealment | Cold, controlling, moralistic; hoards affection; difficulty delegating |
| Hoarding | Driven by obsessional fear (e.g., fear of losing something important or causing harm) | Driven by miserliness/frugality - items are worn out but kept "in case" |
| Treatment response | Good evidence for SSRIs + CBT/ERP | Psychotherapy (psychodynamic, CBT); SSRIs less effective for core traits |
| Key diagnostic rule | When recurrent obsessions AND compulsions are present, diagnose OCD | Reserve the personality disorder diagnosis for significant impairment from obsessive traits WITHOUT true OCD symptoms; if both sets of criteria are met, diagnose both |
The single most important distinction: Ego-dystonic intrusive obsessions + compulsive rituals = OCD. Ego-syntonic perfectionism and rigidity the patient considers rational = OCPD. - Kaplan & Sadock's Synopsis of Psychiatry
PART 2: Classification of OCD
DSM-IV (1994)
- Chapter: Anxiety Disorders
- Code: 300.3
- Diagnostic Criteria:
- (A) Either obsessions OR compulsions:
- Obsessions: Recurrent, persistent thoughts/impulses/images that are intrusive, causing marked anxiety; not simply excessive worry; person tries to ignore, suppress, or neutralize them; recognized as products of their own mind (not thought insertion)
- Compulsions: Repetitive behaviors (hand washing, ordering, checking) or mental acts (praying, counting, silently repeating words) performed in response to an obsession or according to rigid rules; aimed at preventing distress or a dreaded event; clearly excessive or not realistically connected to what they are meant to prevent
- (B) At some point, the person has recognized that the obsessions or compulsions are excessive or unreasonable (this was removed in DSM-5)
- (C) Causes marked distress, is time-consuming (>1 hour/day), or significantly interferes with normal routines, occupational/academic functioning, or social activities/relationships
- (D) Not restricted to another Axis I disorder (if present, content not restricted to that disorder)
- (E) Not due to direct physiological effects of a substance or GMC
- Specifier: "With poor insight" - if most of the time during current episode, person does not recognize obsessions/compulsions as excessive or unreasonable
DSM-5 (2013) - Major Differences from DSM-IV
- Chapter: NEW standalone chapter - "Obsessive-Compulsive and Related Disorders" (removed from Anxiety Disorders)
- Code: 300.3 (F42.2)
- Changes from DSM-IV:
- Removed requirement that patient recognize symptoms as "excessive or unreasonable" - now covers full spectrum including delusional conviction
- Obsessions redefined to include thoughts, urges, or images (not impulses)
- Explicitly states compulsions can be behavioral or mental acts
- Emphasizes functional relationship between obsessions and compulsions
- Added more specific exclusion criteria to differentiate OCD from other disorders
- Specifiers (new):
- Insight level: Good or fair insight | Poor insight | Absent insight/delusional beliefs (when OCD beliefs are held with delusional intensity)
- Tic-related specifier: With/without current or past history of tic disorder
- OCD-Related Disorders in same chapter:
- Body dysmorphic disorder
- Hoarding disorder (new in DSM-5)
- Trichotillomania (hair-pulling disorder)
- Excoriation (skin-picking) disorder (new in DSM-5)
- Substance/medication-induced OCRD
- OCRD due to another medical condition
- Other specified / unspecified OCRD
ICD-10 (WHO, in use until 2022)
- Chapter: F4 - "Neurotic, Stress-related and Somatoform Disorders"
- Code: F42 with subtypes:
- F42.0 - Predominantly obsessional thoughts or ruminations
- F42.1 - Predominantly compulsive acts (obsessional rituals)
- F42.2 - Mixed obsessional thoughts and acts
- F42.8 - Other obsessive-compulsive disorders
- F42.9 - OCD, unspecified
- Key features:
- Remains grouped with neurotic/anxiety disorders under F40-F48
- Does NOT require a functional relationship between obsessions and compulsions
- Does NOT mention mental rituals - only behavioral compulsions recognized
- Uses descriptive guidelines rather than strict operationalized criteria
- Specifiers are content-based (obsessions vs compulsions vs mixed)
- No insight specifier
- OCD and anxiety disorders are in the same grouping
ICD-11 (WHO, 2022 - current)
- Chapter: NEW separate chapter - "Obsessive-Compulsive or Related Disorders" (convergence with DSM-5 approach)
- Code: 6B20 - Obsessive-Compulsive Disorder
- Key changes from ICD-10:
- OCD given its own separate chapter - removed from anxiety/neurotic group
- Insight specifier added (converging with DSM-5)
- Mental rituals now recognized as compulsions
- Functional link between obsessions and compulsions now emphasized
- ICD-11 includes additional disorders not in DSM-5 OCRDs:
- Related disorders in the ICD-11 OCD chapter:
| Code | Disorder | In DSM-5? |
|---|
| 6B20 | OCD | Yes |
| 6B21 | Body dysmorphic disorder | Yes |
| 6B22 | Olfactory reference disorder | No (new in ICD-11) |
| 6B23 | Hypochondriasis/Health anxiety disorder | No (DSM-5 puts it under somatic symptom disorders) |
| 6B24 | Hoarding disorder | Yes |
| 6B25.0 | Trichotillomania | Yes |
| 6B25.1 | Excoriation disorder | Yes |
| 6B2Z | Other/unspecified OCRD | - |
Comparison Table: All 4 Systems
| Feature | DSM-IV | DSM-5 | ICD-10 | ICD-11 |
|---|
| Location | Anxiety Disorders | Own OCRD chapter | Neurotic/Stress disorders (F42) | Own OCRD chapter (6B20) |
| Insight criteria | Must recognize as excessive/unreasonable | Not required; insight is a specifier | Not specified | Specifier (like DSM-5) |
| Mental rituals | Yes, recognized | Yes | No | Yes |
| Functional link | Implied | Explicitly required | Not required | Emphasized |
| Subtypes | None (only poor insight specifier) | Insight + tic-related specifiers | F42.0, F42.1, F42.2 | Insight specifier |
| Additional OCRDs | None | 4 disorders | None (F42 only) | Includes olfactory ref. disorder + hypochondriasis |
PART 3: Treatment-Resistant OCD - Criteria
Operational Definitions
OCD-Resistant (standard): Less than 25% reduction on Y-BOCS despite:
- At least 12 weeks of treatment at the highest tolerated dose of an SSRI or clomipramine
- PLUS at least 30 hours of CBT/ERP
OCD-Refractory (severe): Non-response after:
- 3-6 months of at least 3 antidepressants including clomipramine
- PLUS at least 2 augmentation trials with atypical antipsychotics
Y-BOCS response thresholds:
- Full response = ≥35% Y-BOCS reduction
- Partial response = 25-35% reduction
- Non-response = <25% reduction
- Severe OCD (threshold for surgical consideration) = Y-BOCS ≥28
GAF criterion for surgery: <45 (significant functional impairment)
Note: These definitions are not fully standardized across the literature. Some authors reserve "refractory" exclusively for patients who show no benefit or worsen despite all treatments.
PART 4: Maximum Drug Doses in OCD
OCD requires higher doses than depression and longer trial durations before declaring failure.
First-Line: SSRIs (FDA-Approved for OCD)
| Drug | Starting Dose | Standard Antidepressant Max | Max Anti-obsessional Dose | Supratherapeutic (resistant OCD) |
|---|
| Fluvoxamine | 50 mg/day | 300 mg/day | 300 mg/day | Up to 450 mg/day |
| Fluoxetine | 20 mg/day | 80 mg/day | 80 mg/day | Up to 120 mg/day |
| Sertraline | 50 mg/day | 200 mg/day | 200 mg/day | Up to 400 mg/day |
| Paroxetine | 20 mg/day | 50 mg/day | 60 mg/day | Up to 100 mg/day |
| Escitalopram | 10 mg/day | 20 mg/day | 40 mg/day | Up to 60 mg/day |
| Citalopram | 20 mg/day | 40 mg/day | 40-60 mg/day | Up to 120 mg/day - but avoid: QTc prolongation risk; FDA limits to 40 mg/day |
First-Line / Gold Standard: Clomipramine (TCA)
| Drug | Starting | Maximum | Safety Monitoring |
|---|
| Clomipramine | 25 mg/day | 250 mg/day (FDA max) | Combined plasma level of clomipramine + desmethylclomipramine must be <500 ng/mL; ECG monitoring for QRS widening; seizure risk above 250 mg |
Trial duration rule: Minimum 8-12 weeks total; minimum 4-6 weeks at the maximum tolerated dose before switching or augmenting.
Second-Line Augmentation: Antipsychotics (Atypical)
| Drug | Dose for OCD Augmentation | Notes |
|---|
| Risperidone | 0.5-3 mg/day | Best meta-analytic evidence; first choice |
| Aripiprazole | 5-15 mg/day | Comparable to risperidone; preferred in younger patients; better metabolic profile |
| Quetiapine | 25-200 mg/day | Moderate evidence; useful if comorbid anxiety/insomnia |
| Haloperidol | 2-10 mg/day | Only preferred if comorbid tic disorder; avoid otherwise due to EPS/tardive dyskinesia risk |
| Olanzapine | 5-10 mg/day | Some evidence but metabolic risk limits use |
~1/3 of treatment-resistant OCD patients respond to antipsychotic augmentation.
Glutamatergic Augmentation (Severely Resistant Cases)
| Drug | Dose Range | Evidence |
|---|
| Memantine | Up to 20 mg/day | Multiple RCTs - preliminary efficacy as SRI augmentation |
| Riluzole | Up to 100 mg/day | Multiple RCTs - preliminary efficacy |
| Lamotrigine | Up to 100 mg/day | 2 RCTs - preliminary efficacy |
| Topiramate | Up to 400 mg/day | 3 RCTs - preliminary evidence |
| IV Ketamine | 0.5 mg/kg single infusion | 1 RCT - rapid but transient effect |
| N-acetylcysteine | 1200-3000 mg/day | Open-label data only |
Other Adjunctive Agents
| Drug | Dose | Notes |
|---|
| Buspirone | 15-60 mg/day | Serotonergic augmentation; modest evidence |
| Clonazepam | 1-4 mg/day | Short-term adjunct for anxiety; avoid long-term dependence |
| Lithium | Therapeutic levels | Weak evidence; some case reports |
| Venlafaxine | Up to 375 mg/day | Not FDA-approved for OCD but shows efficacy; useful if comorbid depression |
PART 5: Treatment Flow Algorithm
CONFIRMED OCD DIAGNOSIS
│
▼
STEP 1 - FIRST-LINE (Any SSRI + ERP)
├── Choose SSRI (fluvoxamine, fluoxetine, sertraline, paroxetine, or escitalopram)
├── Start low, titrate to standard maximum dose over 4-6 weeks
├── CBT with Exposure and Response Prevention (ERP): 13-20 sessions
├── Duration: 12 weeks (minimum 4-6 weeks at max tolerated dose)
├── RESPONSE (≥35% Y-BOCS reduction) → CONTINUE 1-2 years maintenance
└── PARTIAL/NO RESPONSE → STEP 2
STEP 2 - DOSE OPTIMIZATION
├── Titrate SSRI to maximum anti-obsessional dose or supratherapeutic dose
│ (e.g., sertraline to 400 mg, fluoxetine to 120 mg)
├── Intensify ERP sessions
├── Additional 4-8 weeks at higher dose
├── RESPONSE → Maintain
└── NO RESPONSE → STEP 3
STEP 3 - SWITCH AGENT
├── Option A: Switch to a different SSRI (full dose trial, 12 weeks)
├── Option B: Switch to CLOMIPRAMINE (most efficacious; titrate to max 250 mg;
│ monitor ECG and plasma levels; keep combined level <500 ng/mL)
├── Continue ERP
├── RESPONSE → Maintain
└── NO RESPONSE = TREATMENT-RESISTANT OCD CRITERIA NOW MET → STEP 4
STEP 4 - AUGMENTATION
├── 4a. Add atypical antipsychotic to SRI:
│ • Risperidone 0.5-3 mg/day (first choice - best evidence)
│ OR Aripiprazole 5-15 mg/day (preferred in young patients)
│ Duration: 8 weeks trial minimum
├── 4b. Consider adding buspirone 15-60 mg/day
├── 4c. Second full course of ERP with an INDEPENDENT therapist
│ (consensual requirement before escalating to interventional)
├── RESPONSE → Maintain
└── NO RESPONSE → STEP 5
STEP 5 - GLUTAMATERGIC / THIRD-LINE PHARMACOLOGY
├── Add memantine (up to 20 mg/day)
│ OR riluzole (up to 100 mg/day)
│ OR lamotrigine (up to 100 mg/day)
│ OR topiramate (up to 400 mg/day)
├── Each agent: 8-12 week trial
├── RESPONSE → Maintain
└── NO RESPONSE + Y-BOCS ≥28 + GAF <45 + OCD ≥5 years → STEP 6
STEP 6 - NEUROMODULATION
├── 6a. rTMS / Deep TMS (non-invasive; first neuromodulation step)
│ • Brainsway H7 coil targeting ACC/medial prefrontal cortex
│ • FDA-cleared for OCD (2018)
│ • Outpatient; well-tolerated
├── 6b. If rTMS fails → proceed to surgical evaluation
└── NO RESPONSE → STEP 7 (Neurosurgical - last resort)
STEP 7 - NEUROSURGICAL PROCEDURES
├── 7a. DEEP BRAIN STIMULATION (DBS) - PREFERRED (reversible/adjustable)
│ • Targets: ALIC/ventral striatum, subthalamic nucleus (STN)
│ • ~60% achieve ≥35% Y-BOCS reduction
│ • FDA HDE approved for severe treatment-resistant OCD
│ • Requires DBS criteria to be fully met (see above)
│
└── 7b. ABLATIVE PROCEDURES (irreversible - used if DBS unavailable/contraindicated)
• Anterior cingulotomy (anterior cingulate cortex)
• Anterior capsulotomy (ALIC - radiosurgery/Gamma Knife or thermal)
• Subcaudate tractotomy (orbitofrontal-subcortical pathway)
• Limbic leucotomy (combination of cingulotomy + subcaudate tractotomy;
broadest intervention; highest efficacy in some series)
Part 6: DBS Criteria Summary (Prerequisite Checklist)
Before a patient can receive DBS for OCD, ALL of the following must be met:
Key References:
- Harrison's Principles of Internal Medicine 22E (2025) - OCD chapter
- Kaplan & Sadock's Synopsis of Psychiatry - OCD and Personality Disorders
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Comparative Nosology
- Frontiers in Psychiatry 2023 (doi:10.3389/fpsyt.2023.1065812) - Therapies for OCD: Current State of the Art
- Pharmacotherapy for Treatment-Resistant OCD - J Clin Psychiatry (PMC7495343)
- OCD for ICD-11: Proposed Changes - Stein et al. (PMC5125074)
- Wolf et al. 2025 (PMID 41138314) - Neurostimulation in treatment-resistant OCD: International overview